Abstract
BackgroundThe role of co-medication with tumour necrosis factor inhibitors (TNFi) is well established in rheumatoid arthritis and ankylosing spondylitis. In psoriatic arthritis (PsA) there is little evidence available on this...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have